sb 216763 has been researched along with Rett Syndrome in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Casal, C; Delgado-Morales, R; Esteller, M; Fourcade, S; Gonzalez-Somermeyer, L; Guil, S; Huertas, D; Jorge-Torres, OC; Llobet, A; Martínez-San Segundo, P; Petazzi, P; Pujol, A; Roa, L; Sáez, MA; Soler, M; Szczesna, K; Velasco, CD | 1 |
1 other study(ies) available for sb 216763 and Rett Syndrome
Article | Year |
---|---|
Inhibition of Gsk3b Reduces Nfkb1 Signaling and Rescues Synaptic Activity to Improve the Rett Syndrome Phenotype in Mecp2-Knockout Mice.
Topics: Animals; Biomarkers; Cells, Cultured; Cerebellum; Dendritic Spines; Disease Models, Animal; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Inflammation; Longevity; Maleimides; Methyl-CpG-Binding Protein 2; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B p50 Subunit; Phenotype; Protein Kinase Inhibitors; Rett Syndrome; Signal Transduction; Survival Analysis; Synapses; Up-Regulation | 2018 |